Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.51 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | PGK2 | P07205 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760867 | 0.86 | P2RY1 (0.53) | ADORA3ADORA1ADORA2B | |
| SCHEMBL10266353 | 0.86 | ADORA3 (0.64) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL23992571 | 0.86 | ADORA3 (0.64) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL23992727 | 0.86 | ADORA3 (0.64) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL10444538 | 0.85 | ADORA3 (0.63) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL24082033 | 0.82 | TLR9 (0.39) | ADORA3ADORA1PGK1PGK2 | |
| SCHEMBL24082054 | 0.82 | TLR9 (0.39) | ADORA3ADORA1PGK1PGK2 | |
| SCHEMBL23761042 | 0.82 | TLR9 (0.39) | ADORA3ADORA1PGK1PGK2 | |
| SCHEMBL23761055 | 0.81 | CYP2C19 (0.39) | ADORA3ADORA1PGK1PGK2NR1I2 | |
| SCHEMBL23760826 | 0.81 | CYP2C19 (0.39) | ADORA3ADORA1PGK1PGK2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |